Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 185

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 185
---

See accompanying notes to consolidated financial statements.

 F-4 

Mosaic ImmunoEngineering, Inc.

Consolidated Statements of Operations

    Year Ended December 31, 

    2024  
    2023 
  
    Operating expenses: 

    Research and development 
    $183,867  
    $435,449 
  
    General and administrative 
     695,788  
     964,319 
  
    Total operating expenses 
     879,655  
     1,399,768 

    Loss from operations 
     (879,655) 
     (1,399,768)

    Other income (expense): 

    Gain on redemption of preferred stock of Holocom 
     –  
     433,000 
  
    Other income 
     42,000  
     – 
  
    Interest income 
     5  
     3,408 
  
    Change in valuation of derivative liability 
     –  
     46,700 
  
    Interest expense on loan payable 
     (6,954) 
     – 
  
    Non-cash interest expense on convertible notes 
     (73,533) 
     (73,333)
  
    Accretion to redemption value on convertible notes 
     (1,446) 
     (15,842)
  
    Total other income, net 
     (39,928) 
     393,933 

    Loss before provision for income taxes 
     (919,583) 
     (1,005,835)

    Provision for income taxes 
     2,400  
     2,400 

    Net loss 
    $(921,983) 
    $(1,008,235)

    Basic loss per common share 
    $(0.13) 
    $(0.14)
  
    Diluted loss per common share 
    $(0.13) 
    $(0.14)

    Weighted average number of common shares outstanding – basic and diluted 
     7,236,447  
     7,236,447 

See accompanying notes to consolidated financial
statements.

 F-5 

Mosaic ImmunoEngineering, Inc.

Consolidated Statements of Stockholders’ Deficit

For the Year Ended December 31, 2024

    Series A  Convertible Voting Preferred Stock